Though a regulatory hitch with migraine drug frovatriptan threatened to derail the company last year, Vernalis plc has turned its fortunes around in the last several months, closing a solid financing in May and now signing an early stage oncology collaboration with GlaxoSmithKline plc. (BioWorld Today) Read More
